{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinomas&page=4",
    "query": {
      "condition": "Neuroendocrine Carcinomas",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 950,
    "total_pages": 95,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinomas&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinomas&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-16T21:40:43.029Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03665285",
      "title": "A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors",
        "Lung Cancer",
        "Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Endometrial Cancer",
        "Melanoma",
        "CRC",
        "Urothelial Carcinoma",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "NC318",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NextCure, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 109,
      "start_date": "2018-10-01",
      "completion_date": "2023-04-11",
      "has_results": true,
      "last_update_posted_date": "2024-03-08",
      "last_synced_at": "2026-11-16T21:40:43.029Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Hackensack, New Jersey + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Gettysburg",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03665285"
    },
    {
      "nct_id": "NCT07517198",
      "title": "Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Small Cell Lung Cancer (SCLC)",
        "High Grade Neuroendocrine Cancer",
        "Small Cell Carcinomas of Non-lung Origin",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Prostate Cancer",
        "Ovarian Cancer",
        "Renal Carcinoma (Clear and Non-clear Cell)",
        "Head and Neck Squamous Cell Carcinoma (HNSCC)",
        "Hepatic Cancer",
        "Gastric Cancer",
        "Triple-negative Breast Cancer (TNBC)"
      ],
      "interventions": [
        {
          "name": "EXS74539",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2026-04-13",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-11-16T21:40:43.029Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Fort Worth, Texas • West Valley City, Utah",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        },
        {
          "city": "West Valley City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07517198"
    },
    {
      "nct_id": "NCT02432963",
      "title": "Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Solid Neoplasm",
        "Bladder Carcinoma",
        "Colon Carcinoma",
        "Estrogen Receptor Negative",
        "Head and Neck Squamous Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "HER2/Neu Negative",
        "Melanoma",
        "Non-Small Cell Lung Carcinoma",
        "Pancreatic Carcinoma",
        "Progesterone Receptor Negative",
        "Rectal Carcinoma",
        "Renal Cell Carcinoma",
        "Soft Tissue Sarcoma",
        "Triple-Negative Breast Carcinoma",
        "TP53 Gene Mutation",
        "Unresectable Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Modified Vaccinia Virus Ankara Vaccine Expressing p53",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2015-12-28",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-16T21:40:43.029Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02432963"
    },
    {
      "nct_id": "NCT00112476",
      "title": "Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Melanoma",
        "Recurrent Renal Cell Cancer",
        "Stage IV Melanoma",
        "Stage IV Renal Cell Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "bryostatin 1",
          "type": "DRUG"
        },
        {
          "name": "temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2005-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-05-03",
      "last_synced_at": "2026-11-16T21:40:43.029Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00112476"
    },
    {
      "nct_id": "NCT00006368",
      "title": "Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Breast Cancer",
        "Gastrointestinal Carcinoid Tumor",
        "Islet Cell Tumor",
        "Lung Cancer",
        "Lymphoma",
        "Melanoma (Skin)",
        "Neoplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "yttrium Y 90-edotreotide",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "1998-01",
      "completion_date": "2003-11",
      "has_results": false,
      "last_update_posted_date": "2013-05-01",
      "last_synced_at": "2026-11-16T21:40:43.029Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006368"
    },
    {
      "nct_id": "NCT06940440",
      "title": "IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Or Metastatic Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "IFx-Hu2.0",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TuHURA Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2026-01-27",
      "completion_date": "2028-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-16T21:40:43.029Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Madison, Wisconsin",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06940440"
    },
    {
      "nct_id": "NCT01683110",
      "title": "Expanded Access of Cabozantinib in Medullary Thyroid Cancer",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Medullary Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-16",
      "last_synced_at": "2026-11-16T21:40:43.029Z",
      "location_count": 5,
      "location_summary": "Stanford, California • Boston, Massachusetts • Detroit, Michigan + 2 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01683110"
    },
    {
      "nct_id": "NCT04160065",
      "title": "Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Merkel Cell Carcinoma",
        "Cutaneous Squamous Cell Carcinoma",
        "Non-Melanoma Skin Cancers"
      ],
      "interventions": [
        {
          "name": "IFx-Hu2.0",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "TuHURA Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2020-03-03",
      "completion_date": "2024-08-13",
      "has_results": false,
      "last_update_posted_date": "2024-09-23",
      "last_synced_at": "2026-11-16T21:40:43.029Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04160065"
    },
    {
      "nct_id": "NCT05479812",
      "title": "Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumor",
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "WTX-124",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Werewolf Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 156,
      "start_date": "2022-08-15",
      "completion_date": "2026-04-22",
      "has_results": false,
      "last_update_posted_date": "2026-11-10",
      "last_synced_at": "2026-11-16T21:40:43.029Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05479812"
    },
    {
      "nct_id": "NCT02174549",
      "title": "Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Gastrointestinal Cancer Metastatic",
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "Tirapazamine",
          "type": "DRUG"
        },
        {
          "name": "Conventional Transarterial Embolization (TAE)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Teclison Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "20 Years to 99 Years"
      },
      "enrollment_count": 25,
      "start_date": "2014-09",
      "completion_date": "2028-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-11-16T21:40:43.029Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02174549"
    }
  ]
}